M6P Therapeutics to Participate in Upcoming Fireside Chat Discussing the Company’s First-in-Class Platform for Lysosomal Enzyme and Gene Delivery at the ROTH Virtual Private Company Forum
– Discussion to include progress and innovations in next-generation therapies for the treatment of lysosomal storage disorders –
ST. LOUIS, Mo., – June 25, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced that Pawel Krysiak, M6PT’s president and chief executive officer, will participate in a fireside chat at the ROTH Virtual Private Company Forum.
- Presenter: Pawel Krysiak
- Host: Zegbeh Jallah, Ph.D.
- Date: Monday, June 28, 2021
- Time: 8:20 a.m. ET
The event will consist of Virtual Panels on Emerging Therapeutics and select Fireside Chats with ROTH Research Analysts. The format will provide an opportunity for C-level executives representing established private healthcare companies in the Biotechnology, Pharmaceuticals, and Medical Technologies verticals to tell their stories.
For more information about the fireside chat, register here or contact your ROTH representative.
About M6P Therapeutics
M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs). M6P Therapeutics’ proprietary S1S3 bicistronic platform has the unique ability to enhance phosphorylation of lysosomal enzymes for both recombinant enzyme and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases. M6P Therapeutics’ team, proven in rare diseases drug development and commercialization, is dedicated to fulfilling the promise of recombinant enzyme and gene therapies by harnessing the power of protein phosphorylation using its S1S3 bicistronic platform. M6P Therapeutics’ mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community. For more information, please visit: www.m6ptherapeutics.com.
Contact us to learn about partnering opportunities with M6P Therapeutics:
Alex Van Rees, SmithSolve